A Safety and Pharmacokinetics Study of Niraparib Plus Apalutamide in Men With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to assess the safety and pharmacokinetics of niraparib when
administered in combination with apalutamide in men with metastatic castration resistant
prostate cancer (mCRPC) who may or may not have deoxyribonucleic acid (DNA)-repair
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society